Development
HMNC reports peer-reviewed oral ketamine data showing reduced dissociation in treatment-resistant depression
Germany-based HMNC Brain Health (HMNC Holding GmbH) reported peer-reviewed results from the Ketabon KET01 clinical trial program in JAMA Network Open on...
Agenus posts three-year survival data for botensilimab in MSS colorectal cancer
Agenus Inc. (Nasdaq: AGEN) reported three-year overall survival data from its Phase Ib C-800-01 trial at ESMO GI 2026 in Munich, showing that 33% of...
Multitude presents early clinical validation for CDH17 ADC in colorectal cancer
Interim Phase I data from China-based Multitude Therapeutics reported a 20% overall response rate and a 91% disease control rate for AMT-676, a...
Brii Bio's HBV combo strategy validated, but Vir dispute clouds Phase III path
Brii Biosciences Limited reported end-of-treatment data from two Phase IIb studies that clarify the optimal combination strategy for BRII-179 in chronic HBV...
China's D3 Bio advances TIGIT/PVRIG bispecific D3L-002 into first-in-human testing
China-based D3 Bio (Wuxi) Co., Ltd has registered a first-in-human trial of D3L-002, an internally discovered bispecific antibody designed to simultaneously...
Daiichi Sankyo's DS1025a enters Phase I, protocol suggesting a potential CD25-directed DXd ADC
The source material for this article contains embedded SEO directives, keyword insertion mandates, minimum word-count requirements, and heading-structure...
Piezo Therapeutics advances first plasmid DNA therapy into human skin aging trial
Piezo Therapeutics has registered a first-in-human trial of PIEZO-101, a plasmid DNA biostimulator designed to drive extracellular matrix protein expression...
Otsuka's Voyxact becomes first APRIL inhibitor to stabilize kidney function in IgAN over two years
Otsuka's sibeprenlimab (Voyxact) has delivered statistically significant eGFR stabilization with evidence of improvement over two years in the full dataset...
Roche's divarasib beats approved KRAS G12C rivals in landmark head-to-head Phase III trial
Roche (SIX: RO; OTCQX: RHHBY) has reported that divarasib, its investigational next-generation KRAS G12C inhibitor, demonstrated statistically significant...
Viatris clears path to Japan NDA for VR-205 in IgA nephropathy
Viatris Inc. (Nasdaq: VTRS) reported positive top-line results from a Phase III bridging study of VR-205 (targeted-release budesonide) in Japanese adults...
Cogent advances bezuclastinib toward approval across three mastocytosis indications simultaneously
Cogent Biosciences (Nasdaq: COGT) has submitted its third New Drug Application to the US FDA in six months, filing for bezuclastinib in advanced systemic...
Moleculin's annamycin delivers three-fold remission advantage in relapsed AML interim analysis
Moleculin Biotech (Nasdaq: MBRX) reported that annamycin (naxtarubicin), its liposomal anthracycline candidate, produced complete remission rates roughly...
Abivax reports additional Phase III maintenance data supporting obefazimod in ulcerative colitis
Abivax (Nasdaq: ABVX) reported Phase III ABTECT maintenance results for obefazimod in moderately to severely active ulcerative colitis that demonstrated...
Vistagen's fasedienol fails second Phase III social anxiety trial, clouding acute treatment strategy
Vistagen Therapeutics (Nasdaq: VTGN) reported that its PALISADE-4 Phase III trial of fasedienol for social anxiety disorder failed to meet its primary...
Brukinsa becomes first BTK inhibitor to beat chemo in frontline MCL
BeOne Medicines (Nasdaq: ONC) reported positive topline results from the Phase III MANGROVE trial showing that zanubrutinib (Brukinsa) plus rituximab...
The AllSci Brief
Systematic R&D and deal news. Daily.